Background: Meningococcal meningitis occurs globally and the predominant serogroups vary by geographic region. Vaccines against serogroups A, B, C, Y and W-135 are available in Canada.
Introduction
The goal of this Statement is to provide guidance to health care professionals for the prevention of meningococcal disease in international travellers from Canada.
Methods
This Statement was developed by a working group of the Committee to Advise on Tropical Medicine and Travel (CATMAT). It was developed to compliment a thorough literature review and analysis which was conducted as part of the development of the National Advisory Committee on Immunization's (NACI) recommendations in the Canadian Immunization Guide (1) . CATMAT has considered the need for protection and the potential for adverse effects of vaccination. The Statement represents a narrative review of the travel medicine literature on meningococcal vaccines and CATMAT's expert opinion. The recommendations do not include a description of the strength of the recommendation or grade of the quality of evidence as has been done in previous CATMAT statements. Each member of CATMAT is a volunteer and none declared a relevant conflict of interest.
Background
Meningococcal disease is caused by a Gram negative bacterium, Neisseria meningitidis. Neisseria are divided into 12 serogroups according to the immunological reactivity of their capsular polysaccharide (2) . The five major serogroups most commonly associated with invasive disease are A, B, C, Y and W-135 (2, 3, 4) .
Person-to-person transmission occurs by close contact with respiratory secretions or saliva of infected persons (1, 4) . Humans are the only reservoir (5) . Asymptomatic carriage occurs, and at any time, 5%-10% of the population may be carriers of N. meningitidis (1, 3, 4) . Invasive disease is an infrequent consequence of nasopharyngeal colonization (6) .
Invasive meningococcal disease generally occurs one to fourteen days after exposure and usually presents as an acute febrile illness with rapid onset and features of meningitis or septicemia (meningococcemia), or both and a characteristic non-blanching petechial or purpuric rash. Symptoms of meningococcal meningitis include intense headache, fever, nausea, vomiting, photophobia and stiff neck. Meningococcemia often involves hypotension, acute renal failure, hemorrhage and multi organ failure (1, 4) . Fatality rates are approximately five to ten percent even with prompt antimicrobial treatment in healthcare facilities (5) . Up to one-third of survivors may have longterm sequelae including hearing loss, neurologic disabilities and digit or limb amputations (1, 2, 4) .
Epidemiology
N. meningitidis is found worldwide. In most countries, N. meningitidis is recognized as a leading cause of meningitis and fulminant septicemia and is a significant public health problem. However, population-based surveillance with laboratory confirmation and strain characterization is still not attainable in many countries throughout the world (7) . Surveillance data from many countries are incomplete or lacking and there is currently no reliable global burden estimate (8) .
Meningococcal meningitis occurs globally and the predominant serogroup varies by geographic region. In Australia, New Zealand and Europe, serogroup B predominates, followed by serogroup C (7, 9) . Serogroups B and C predominate in the United States and Canada, followed by serogroup Y (7, 9) . The serogroup distribution across Latin America, South America and the Caribbean varies, with serogroups B and C predominating in some countries and W-135 and Y in others (9) . Little is known about the epidemiology of meningococcal disease in Asia and neighbouring areas (7, 9) . Different patterns of invasive meningococcal disease are seen across Africa (7). This is the case in the African meningitis belt, a region in sub-Saharan Africa extending from Senegal in the west to Ethiopia in the East (Figure  1) , with a population of approximately 400 million (10) . During the dry season (approximately December through June), the incidence rate of meningococcal disease can reach as high as 1,000 cases per 100,000 population. In non-epidemic periods, the rate of meningococcal disease in this region is roughly five to ten cases per 100,000 population (4, 8) . Risk is highest in travellers to the meningitis belt who have prolonged contact with local populations during an epidemic.
Because of the crowded conditions of the Hajj and Umrah pilgrimage to Saudi Arabia and high carrier rates of N. meningitidis among pilgrims, outbreaks of meningococcal disease have historically been a problem (4, 11) . The Hajj pilgrimages in 2000 and 2001, for example, were associated with large outbreaks of serogroup W-135 in returning pilgrims and their contacts.
Although people of any age can develop disease, endemic disease occurs most often in children and adolescents, whereas in meningococcal epidemics, rates may rise in older children and young adults (1, 8) . 
Vaccine recommendations for Canadian travellers
Meningococcal vaccine recommendations vary by characteristics of the traveller (e.g., age, medical conditions, etc.) and the travel destination. Specific recommendations for travellers from Canada are outlined below. For healthy travellers to a destination where risk of meningococcal transmission is high, please see Table 1 Routine vaccination programs with conjugate serogroup C vaccine have been implemented in every Canadian province and territory (1). Independent of travel plans, the traveller should be up-to-date for age in accordance with their provincial/territorial immunization schedule (12) .
Travellers with underlying medical conditions
Vaccination is recommended for children and adults at increased risk of invasive meningococcal disease regardless of destination ( Table 1) . Refer to the Canadian Immunization Guide for detailed information on recommended products, scheduling and dosage (1). Booster doses should be given every five years after the last dose.
Booster doses:
Because of unknown duration of protection after immunization, the need for a booster dose is yet to be determined. 1 Based on available published data in this age group, Menveo™ should be used because it has been found to be safe and immunogenic. Routine meningococcal C conjugate vaccine does not need to be administered in addition to Menveo™. 2 Men-C-ACYW-135 vaccines are not authorized for use in those 56 years of age and older; however, based on limited evidence and expert opinion their use is considered appropriate (2). 3 In Canada, 4CMenB has been authorized for use in individuals from two months through 17 years of age. 4 The manufacturer of Nimenrix™ has not yet determined the need for a booster dose; however NACI recommends periodic booster for individuals at highrisk for IMD or who have ongoing risk of exposure (2).  Adults and children aged two years and older must be vaccinated with quadrivalent meningococcal vaccine (serogroups A, C, Y and W-135) (13) .  Children between three months and two years of age must be vaccinated with two doses of meningococcal A vaccine, with a three-month interval between the two doses (13) .  The vaccination must have been received not more than three years and not less than ten days before arrival in Saudi Arabia (13) .
Travellers to the Hajj and Umrah pilgrimages
In general, travellers to this region do not need to receive 4CMenB vaccine unless there is evidence of a hyperendemic strain or an outbreak that is known to be caused by serogroup B that can be prevented by the vaccine.
Refer to the recommendations in the Government of Canada's travel health notices for pilgrims to the Hajj and Umrah posted each year in late summer to early fall for the most up-to-date information to ensure that individual travellers have appropriate vaccine documentation (14).
Travellers to sub-Saharan Africa
Quadrivalent meningococcal vaccine (serogroups A, C, Y, W-135) is recommended for travellers to the African meningitis belt (Figure 1) or countries outside the usual boundaries where epidemics have occurred, especially those who will be living or working there, or may be in close contact with the local population through school, accommodation, etc.
Immunization against serogroup C alone is not considered adequate for individuals travelling to this region. A single dose of any of the available quadrivalent conjugate meningococcal vaccines may be used for the immunization of individuals two years of age and older (2) . Men-C-ACYW-135-CRM (Menveo™) is recommended for immunization of individuals two months to less than two years of age. Refer to the Canadian Immunization Guide for detailed information and schedules (1).
Other considerations for travellers
 Travellers to areas with current epidemics or heightened disease activity should be vaccinated, regardless of duration of exposure. The Government of Canada's travel health notices for recognized areas of new and recent meningococcal activity are released and updated regularly on travel.gc.ca (14).  IMD has historically occurred in schools, colleges and other places where large numbers of adolescents and young adults congregate. Individuals travelling to these settings may consider receipt of vaccine for serogroups B and A,C,Y, W-135 at least two weeks prior to arrival (5).  Individuals travelling to engage in research, industrial and/or clinical laboratory settings with the potential for routine exposure to N. meningitidis should be vaccinated with Men-C-ACYW-135 vaccine and 4CMenB vaccine. Re-vaccination of laboratory staff at ongoing risk of exposure should be done at routine five-year intervals (1) . Laboratory staff at ongoing risk of exposure should be re-vaccinated at routine fiveyear intervals with Men-C-ACYW-135 vaccine (1) . Because of unknown duration of protection after immunization, the need for a booster dose of 4CMenB vaccine is yet to be determined (9) .  There is no evidence to recommend routine meningococcal immunization of individuals travelling to work as health care providers; nosocomial transmission of IMD is very uncommon (1).  Travellers to developed countries should follow the meningococcal immunization recommendations of the destination country (15) . 
Additional vaccine characteristics and usage

Contraindications and precautions
Contraindicated for individuals with a history of anaphylaxis after a previous dose of the vaccine or individuals with a proven anaphylactic reaction to any component of the vaccine or its container (1) .
Administration of meningococcal vaccine should be postponed in Contraindicated for individuals with a serious allergy to any vaccine component or previous dose (2). individuals with moderate or severe acute illness; individuals with minor acute illnesses (with or without fever) may be vaccinated (1).
Pregnancy and breastfeeding
Conjugate meningococcal vaccines have not been studied in pregnancy; however, the use of the vaccine may be considered, if indicated (1, 3) . Inactivated vaccines, such as meningococcal vaccines, may be administered to women who are breastfeeding (1).
There are no studies of 4CMenB vaccine in pregnant or lactating women.
Immunocompromised travellers
Meningococcal vaccine is recommended for certain high-risk individuals as outlined above. When considering immunization of an immunocompromised person, consultation with the individual's attending physician may be of assistance. For complex cases, referral to a physician with expertise in immunization and/or immunodeficiency is advised.
Concurrent administration with other vaccines
Quadrivalent conjugate vaccines may be administered concomitantly with adolescent and adult ageappropriate vaccines at different injection sites using separate needles and syringes (1) .
A review of the concomitant use of 4CMenB with other vaccines can be found in the NACI Statement on the Advice for the use of 4CMenB Vaccine (9) .
Interchangeability of vaccines
Any of the quadrivalent conjugate vaccines may be used for revaccination, regardless of which meningococcal vaccine was used for initial vaccination (1) . When possible, the infant series should be completed with the same vaccine.
Not applicable.
General precautions
Travellers should be advised to practice good hand hygiene interventions and avoid activities that promote the exchange of respiratory secretions, such as sharing drinks, cigarettes, lipstick, etc. Avoid overcrowding in confined spaces. Following close contact with an individual infected with meningococcal disease, medical advice should be sought regarding possible chemoprophylaxis and vaccination (5) .
Conclusion
Meningococcal vaccination is the most effective measure for preventing IMD. The Government of Canada's travel health notices identify areas of new and recent meningococcal activity and are updated regularly (14).
